What Is Haemophilus Influenzae Beta-Lactamase-Negative?

Haemophilus influenzae beta-lactamase-negative refers to strains of the bacterium Haemophilus influenzae that do not produce beta-lactamase, the enzyme most bacteria use to destroy penicillin-type antibiotics. When these strains are also resistant to ampicillin, they carry the designation BLNAR, short for beta-lactamase-negative ampicillin-resistant. Instead of breaking down the drug, BLNAR strains dodge it by reshaping a key protein target so the antibiotic can no longer bind effectively. This subtle distinction has become one of the more urgent problems in infectious-disease microbiology, because BLNAR strains are rising fast in many countries and are harder to detect and treat than their enzyme-producing counterparts.

How H. Influenzae Normally Resists Antibiotics

Most ampicillin-resistant H. influenzae produce a beta-lactamase enzyme, usually the TEM-1 type, that chews apart the beta-lactam ring in penicillin-family drugs, rendering them useless. These strains are labeled BLPAR (beta-lactamase-positive ampicillin-resistant). Adding a beta-lactamase inhibitor such as clavulanic acid, the companion drug in amoxicillin-clavulanate, neutralizes the enzyme and restores the antibiotic’s killing power. That strategy has been a clinical staple for decades.

BLNAR strains break this logic. They produce no beta-lactamase at all, so a standard lab test for the enzyme comes back negative and the strain looks susceptible at first glance. Yet the bacterium still shrugs off ampicillin. Because the resistance has nothing to do with enzyme production, adding clavulanic acid does not help. A third, more troublesome category exists as well: BLPACR strains carry both the enzyme and the protein-target mutations, so they resist amoxicillin-clavulanate from two directions at once.¹

The Protein Target That Changes Shape

Beta-lactam antibiotics work by locking onto proteins called penicillin-binding proteins (PBPs) that the bacterium needs to build its cell wall. In H. influenzae, the critical target is PBP3, encoded by a gene called ftsI. PBP3 plays a central role in forming the wall that divides a bacterial cell in two when it reproduces. When ampicillin binds to PBP3, cell-wall construction stalls and the bacterium dies.

In BLNAR strains, mutations in the ftsI gene change the shape of PBP3 just enough that the antibiotic can no longer latch on properly. Studies measuring the binding strength of radiolabeled penicillin confirmed that BLNAR isolates have reduced drug affinity at PBP3, and in some strains the affinity of additional PBPs is also diminished.² Computational modeling has shown that the mutations affect not only the immediate drug-binding pocket but also distant parts of the protein structure, opening the catalytic site and increasing the flexibility of a loop that controls the enzyme’s activity.³

Groups and Mutation Patterns

Researchers classify BLNAR strains into groups based on which amino acid swaps appear in the ftsI gene. The original grouping, established in 2001, sorts isolates into three resistance groups defined by distinct substitution patterns in the part of PBP3 that does the enzymatic work.² In broad terms:

Group I: A single swap near a conserved region of PBP3, replacing arginine at position 517 with histidine. These strains tend to have modest ampicillin resistance.
Group II: A swap of asparagine to lysine at position 526. This is the most common mutation worldwide.
Group III: Multiple simultaneous swaps, including changes near a second conserved motif in addition to the 526 substitution, producing higher resistance levels.

In a large Spanish survey, over 93% of BLNAR strains carried mutations at the conserved KTG motif, with the asparagine-to-lysine swap at position 526 appearing in roughly 84% and the arginine-to-histidine swap at position 517 in about 9%.⁴ Group III strains are particularly worrying because their multiple mutations also reduce susceptibility to certain cephalosporins, extending resistance beyond basic penicillins. Korean data showed isolates carrying four to seven mutations simultaneously at known resistance sites in PBP3.⁵

A Japanese study found that high-BLNAR strains, those with the most clinically significant resistance, made up 92% of all BLNAR isolates tested, and nearly all carried either the 526 or 517 substitution alongside a third swap at position 385.⁶ When researchers transferred the mutated ftsI gene into a susceptible lab strain, the resulting bacteria showed typical BLNAR-level ampicillin resistance, confirming that the gene alone is sufficient to confer the trait.⁷

How BLNAR Spreads Between Bacteria

H. influenzae is naturally competent, meaning it can pick up free-floating DNA from its surroundings and stitch it into its own genome. This matters because BLNAR resistance can spread not just through bacterial reproduction but through horizontal gene transfer. Researchers have found mosaic versions of the ftsI gene in clinical isolates, with segments that originated from a related species, Haemophilus haemolyticus, spliced into the H. influenzae gene through recombination.⁸

Lab experiments confirmed that when a susceptible strain was incubated alongside a BLNAR strain, the resistance gene transferred at measurable frequencies. Genetically unrelated BLNAR strains from different hospitals have been found carrying identical ftsI sequences, which is strong evidence that the gene moved sideways between lineages rather than evolving independently in each one.⁹ Inadequate antibiotic exposure may accelerate this process by selecting for mutations in ftsI and creating environments where resistant strains dominate.¹⁰

Rising Prevalence Around the World

BLNAR rates have climbed steeply in many countries over the past two decades. Japanese surveillance documented the prevalence jumping from 0% in 1999 to over 21% by 2002 among invasive type b isolates.¹¹ By 2014, BLNAR strains accounted for more than half of all H. influenzae isolates in some Japanese datasets, and these strains were also acquiring resistance to non-beta-lactam drugs.¹²

Other regions tell a similar story, if with different numbers. A Korean nationwide surveillance study found about 6% of respiratory isolates were BLNAR, with group III strains identified for the first time in the country.¹³ In British Columbia, Canada, 31% of invasive non-typeable strains were genotypic BLNAR.¹⁴ In Spain, over half of all isolates tested in one large survey were classified as BLNAR.⁴ China has seen a parallel increase in BLNAR detection after widespread uptake of the Hib vaccine shifted the balance of circulating strains toward non-typeable varieties.¹⁵

Why BLNAR Is Hard to Catch in the Lab

One reason BLNAR strains slipped under the radar for years is that their resistance levels are often low. Many BLNAR isolates, particularly those in group I or group II with a single mutation, show ampicillin resistance values that hover in the gray zone between susceptible and resistant. Separating them from truly susceptible bacteria using standard susceptibility tests is a genuine challenge.¹⁶ A Belgian study found that 30% of isolates sent to a national reference center were classified as beta-lactamase-negative and ampicillin-sensitive under standard guidelines, yet all of them showed resistance values at or above the threshold when tested more precisely.¹⁷

Disc diffusion, the method many routine labs use, performs unevenly for BLNAR detection. A head-to-head comparison of European (EUCAST) and American (CLSI) disc diffusion methods found that EUCAST correctly flagged all 18 confirmed BLNAR isolates in a set of 100 strains, while CLSI disc diffusion caught only 5 of 18.¹⁸ The gold standard for identifying these strains is molecular: sequencing the ftsI gene to look for the specific amino acid substitutions. PCR-based screening methods exist, but even they have pitfalls. One study evaluating PCR primers designed to detect the common N526K substitution found that certain primer sets were 100% accurate, while others failed to amplify strains where the same substitution was encoded by a different codon, highlighting the genetic variability that can trip up even targeted molecular tools.¹⁹

What Infections BLNAR Strains Cause

H. influenzae causes a wide spectrum of illness, from ear infections and sinusitis to pneumonia and, less commonly, meningitis and bloodstream infections. BLNAR strains appear across all of these. In a Japanese pediatric study, BLNAR isolates were found in about 61% of pneumonia cases, 49% of acute ear infections, and 29% of meningitis cases.²⁰ A Bulgarian study of children with acute ear infections found that 12.5% of H. influenzae isolates were BLNAR, with the vast majority of all H. influenzae ear infection strains being non-typeable.²¹

Children carry a disproportionate share of the burden. Pediatric isolates from lower respiratory tract infections in one Chinese dataset showed higher ampicillin resistance rates than adult isolates, though only the difference in azithromycin resistance reached statistical significance.²² The pediatric tilt makes sense biologically: young children have immature immune systems, attend daycare settings that promote bacterial transmission, and receive frequent antibiotic courses that create selection pressure favoring resistant strains.

BLNAR, Biofilms, and Recurrent Ear Infections

Ear infections that keep coming back or fail to clear with standard antibiotics are a particular frustration for parents and clinicians. Research has pointed to a tandem of traits in H. influenzae that helps explain treatment failures: antibiotic resistance and biofilm formation. In a study of 48 isolates from children with treatment-failure or recurrent ear infections, about 83% formed biofilms and roughly a third carried beta-lactam resistance mechanisms, with PBP3 modifications being the most common at about 23%. Over a quarter of the isolates had two or more of these traits at once.²³ Interestingly, the strains with lower amoxicillin resistance actually formed denser biofilms, suggesting that biofilm growth and drug resistance may be somewhat independent survival strategies the bacterium employs.

Treatment When Ampicillin Fails

For straightforward BLNAR infections, the good news is that several other antibiotics remain effective. A pharmacokinetic/pharmacodynamic modeling study evaluating invasive H. influenzae infections found that virtually all tested antibiotics achieved full or near-full target attainment against BLNAR strains, with the notable exception of ampicillin and amoxicillin for beta-lactamase-producing bacteria.²⁴ Third-generation cephalosporins and fluoroquinolones generally retain activity against most BLNAR strains, though group III isolates with multiple PBP3 mutations can push cephalosporin resistance higher.

The trickier concern is the emerging pattern of multidrug resistance. BLNAR strains are not just resistant to ampicillin; they increasingly show reduced susceptibility to non-beta-lactam drugs as well, with multidrug-resistant H. influenzae emerging as a recognized phenomenon.¹² This is the trajectory that worries infectious-disease specialists. Losing ampicillin is manageable. Losing multiple drug classes simultaneously narrows options fast, particularly for children with recurrent infections who have already cycled through first-line treatments.

The Hib Vaccine and What It Does Not Cover

The Hib conjugate vaccine, one of the great success stories of modern immunization, targets H. influenzae type b, a specific capsulated serotype that once caused the majority of invasive disease in children. The vaccine has been spectacularly effective at eliminating type b infections in countries with high coverage. But H. influenzae includes many other serotypes and, importantly, a large population of non-typeable strains (NTHi) that carry no capsule at all. The Hib vaccine does nothing against these.

Most BLNAR strains are non-typeable. As the Hib vaccine eliminated its target, non-typeable strains filled the ecological space. Chinese surveillance after two decades of Hib vaccine use found widespread NTHi with high genetic diversity and increasing BLNAR detection.¹⁵ Italian data similarly showed an increasing trend in invasive NTHi disease, with ampicillin resistance mediated by both beta-lactamase and altered PBP3 on the rise, and specific genetic lineages linked to each resistance mechanism.²⁵ No licensed vaccine currently prevents NTHi infection, though several candidates are in development, largely aimed at reducing chronic obstructive pulmonary disease exacerbations in adults.

Why “Low-Level” Resistance Still Matters

A persistent misconception is that BLNAR strains with low ampicillin resistance levels are clinically insignificant. Their MIC values may be only a few times above the susceptible cutoff, and some labs do not flag them at all. But low-BLNAR strains represent the majority of the BLNAR population in Europe and the United States, and the evidence suggests they serve as a stepping stone.¹⁶ A strain with one PBP3 mutation can acquire additional mutations over time, or pick up a more heavily mutated ftsI gene from a neighboring bacterium through horizontal transfer. Mutations in the ftsI gene accumulate: the jump from group II to group III involves adding mutations near a second conserved motif, which substantially raises resistance to both ampicillin and cephalosporins.²⁶

The practical implication is that even borderline-resistant strains should not be dismissed. They are part of a resistance pipeline. Underdetecting them in the lab means underestimating how many resistant strains are actually circulating, which in turn means clinicians may keep prescribing ampicillin or amoxicillin for infections that are unlikely to respond fully. That selective pressure, repeated across millions of prescriptions, is exactly what drives the mutation count upward.

Comparing the Resistance Mechanisms Side by Side

It helps to see the four main categories of H. influenzae ampicillin susceptibility in one place, since the acronyms can blur together:

BLNAS: Beta-lactamase-negative, ampicillin-susceptible. No enzyme, no PBP3 mutations. Fully treatable with ampicillin or amoxicillin.
BLPAR: Beta-lactamase-positive, ampicillin-resistant. Produces the enzyme. Adding a beta-lactamase inhibitor (like clavulanic acid) typically restores drug activity.
BLNAR: Beta-lactamase-negative, ampicillin-resistant. No enzyme, but PBP3 is altered. Clavulanic acid does not help because there is no enzyme to inhibit.
BLPACR: Beta-lactamase-positive, amoxicillin-clavulanate-resistant. Both mechanisms present: the strain produces the enzyme and has PBP3 mutations, so even the inhibitor combination fails.

A Korean surveillance dataset illustrates the relative proportions in one country: about 42% of respiratory isolates were fully susceptible (BLNAS), 47% were classic enzyme producers (BLPAR), 6% were BLNAR, and 5% were BLPACR.¹³ Those figures shift substantially by geography and time period, with Japan showing dramatically higher BLNAR rates and parts of Europe seeing rapid increases as well.

Molecular Surveillance and Where the Science Is Headed

Conventional antibiotic susceptibility testing, the kind most hospital labs run, was designed around beta-lactamase detection because that was historically the dominant resistance mechanism in H. influenzae. The disc-based and broth-dilution methods can struggle with BLNAR, as the Belgian and EUCAST/CLSI comparison studies showed. Whole-genome sequencing offers the most reliable identification: it picks up every ftsI mutation pattern, distinguishes true BLNAR from low-level susceptible strains, and identifies BLPACR strains that carry both mechanisms.¹⁸ As sequencing costs continue to drop, some reference laboratories now routinely genotype H. influenzae resistance rather than relying solely on phenotypic tests.

At the drug-design level, the structural work on PBP3 and its partner protein FtsW has opened new lines of inquiry. If mutations in the active site of PBP3 are what defeat current antibiotics, researchers are asking whether alternative binding regions on the FtsW-PBP3 complex could be targeted instead.³ That work remains early-stage, but it reflects a broader recognition that simply tweaking existing beta-lactam scaffolds may not be enough if the bacteria keep reshaping the protein those scaffolds are designed to hit.